Host Defense Regulation by HTLV-1

HTLV-1 的宿主防御调节

基本信息

项目摘要

Adult T cell leukemia-lymphoma (ATLL) is an aggressive and generally fatal tumor associated with Human T cell Leukemia Virus Type 1 (HTLV-1). ATLL, a CD4 helper T cell malignancy, presents clinically as either a chronic disease that may progress, as an acute leukemia or high grade lymphoma. ATLL pafients fare very pooriy with conventional chemotherapeutic regimens, however therapy with azidothymidine (AZT) and interferon alpha (IFN-a) has produced long-term clinical remissions in a subset of patients. Little is known of the molecular pathogenesis of ATLL. Suitable animal models for the disease have been lacking and HTLV-1 transformed lines differ substanfially from the primary tumors. Most research has centered on the role of the viral oncoprotein tax although it is not expressed in primary tumors. Research on HTLV-1 and oncogenesis is further complicated by the prolonged latency between the time of infection and the development of overt disease. In order to study this tumor and identify subgroups of ATLL that may be amenable to AZT/IFNo (or other) therapies one must have access to a large number of primary isolates. HTLV-1 related diseases are a significant health care problem in certain US communities, in afro-Caribbean and afro-Latin communities. Miami is an endemic area for the HTLV-1 virus as is Salvador, the capital of the northeastern Brazilian state, Bahia. Through a collaboration between the University of Miami and the Federal University of Bahia we have identified several important molecular features related to the pathogenesis, therapy and prognosis of ATLL. We have defined two forms of the disease, one that is responsive to AZT/IFNa and another that is resistant. Response or lack thereof correlates with nuclear NF-kB subunit composifion and IFN signaling properties. We have also found that patients in remission while on long-term antiviral therapy have persistent T cell clones detectable in peripheral blood mononuclear cells (PBMC's). We propose to study primary ATLL in pafients at our institution and at our collaborators site. We will follow patients enrolled on an anfiviral clinical trial to determine the molecular characteristics of sensitive and resistant disease. This translational study which is thematically linked to this overall proposal (IFN and innate immune signaling) has great potential to begin to elucidate the molecular processes of ATLL progression as well as define the subset of pafients most likely to benefit from therapy. RELEVANCE (See instructions): HTLV-1 related ATLL is a deadly disease that predominanfiy affects Afro-Caribbean and African Americans in our community (South Florida). The disease is also quite common in Afro-Lafin populafions. The study of ATLL presents some technical difficulties and investigation of the actual tumor requires access to primary pafient material. We present in our proposal a translafional study of the biology of AZT/IFNa sensifive and resistant ATLL coupled with a clinical trial. We have substanfial experience with this disease and our project is closely integrated with the two other proposals in this application.
成人T细胞白血病淋巴瘤(ATLL)是一种与人类T相关的侵袭性和通常致命的肿瘤

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Joseph David Rosenblatt其他文献

Joseph David Rosenblatt的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Joseph David Rosenblatt', 18)}}的其他基金

Augmentation of Anti-Tumor Activity in the Absence of B Cells
在没有 B 细胞的情况下增强抗肿瘤活性
  • 批准号:
    7226411
  • 财政年份:
    2006
  • 资助金额:
    $ 26.02万
  • 项目类别:
HSV Amplicon Activation of Innate and Adaptive Immunity
HSV 扩增子激活先天性和适应性免疫
  • 批准号:
    6922933
  • 财政年份:
    2004
  • 资助金额:
    $ 26.02万
  • 项目类别:
HSV Amplicon Activation of Innate and Adaptive Immunity
HSV 扩增子激活先天性和适应性免疫
  • 批准号:
    7081232
  • 财政年份:
    2004
  • 资助金额:
    $ 26.02万
  • 项目类别:
HSV Amplicon Activation of Innate and Adaptive Immunity
HSV 扩增子激活先天性和适应性免疫
  • 批准号:
    7252495
  • 财政年份:
    2004
  • 资助金额:
    $ 26.02万
  • 项目类别:
HSV Amplicon Activation of Innate and Adaptive Immunity
HSV 扩增子激活先天性和适应性免疫
  • 批准号:
    6732448
  • 财政年份:
    2004
  • 资助金额:
    $ 26.02万
  • 项目类别:
HSV Amplicon Activation of Innate and Adaptive Immunity
HSV 扩增子激活先天性和适应性免疫
  • 批准号:
    7474033
  • 财政年份:
    2004
  • 资助金额:
    $ 26.02万
  • 项目类别:
CHEMOKINE ENHANCED IMMUNE THERAPY OF LYMPHOMA
趋化因子增强淋巴瘤的免疫治疗
  • 批准号:
    6191801
  • 财政年份:
    2000
  • 资助金额:
    $ 26.02万
  • 项目类别:
CHEMOKINE ENHANCED IMMUNE THERAPY OF LYMPHOMA
趋化因子增强淋巴瘤的免疫治疗
  • 批准号:
    6514721
  • 财政年份:
    2000
  • 资助金额:
    $ 26.02万
  • 项目类别:
CHEMOKINE ENHANCED IMMUNE THERAPY OF LYMPHOMA
趋化因子增强淋巴瘤的免疫治疗
  • 批准号:
    6378117
  • 财政年份:
    2000
  • 资助金额:
    $ 26.02万
  • 项目类别:
CHEMOKINE ENHANCED IMMUNE THERAPY OF LYMPHOMA
趋化因子增强淋巴瘤的免疫治疗
  • 批准号:
    6555041
  • 财政年份:
    2000
  • 资助金额:
    $ 26.02万
  • 项目类别:

相似海外基金

Targeting Menin in Acute Leukemia with Upregulated HOX Genes
通过上调 HOX 基因靶向急性白血病中的 Menin
  • 批准号:
    10655162
  • 财政年份:
    2023
  • 资助金额:
    $ 26.02万
  • 项目类别:
Rapid Acute Leukemia Genomic Profiling with CRISPR enrichment and Real-time long-read sequencing
利用 CRISPR 富集和实时长读长测序进行快速急性白血病基因组分析
  • 批准号:
    10651543
  • 财政年份:
    2023
  • 资助金额:
    $ 26.02万
  • 项目类别:
Experimental and preclinical modeling of NUP98-rearranged acute leukemia
NUP98重排急性白血病的实验和临床前模型
  • 批准号:
    10829603
  • 财政年份:
    2023
  • 资助金额:
    $ 26.02万
  • 项目类别:
Rapid Acute Leukemia Genomic Profiling with CRISPR enrichment and Real-time long-read sequencing
利用 CRISPR 富集和实时长读长测序进行快速急性白血病基因组分析
  • 批准号:
    10839678
  • 财政年份:
    2023
  • 资助金额:
    $ 26.02万
  • 项目类别:
A Systems Epidemiology Approach for Predicting Methotrexate Neurotoxicity in Pediatric Acute Leukemia
预测儿童急性白血病甲氨蝶呤神经毒性的系统流行病学方法
  • 批准号:
    10655716
  • 财政年份:
    2023
  • 资助金额:
    $ 26.02万
  • 项目类别:
Anti-CD25 Radioimmunotherapy and Total Marrow Irradiation for Treatment of Relapsed and Refractory Acute Leukemia
抗CD25放射免疫治疗和全骨髓照射治疗复发难治性急性白血病
  • 批准号:
    10435886
  • 财政年份:
    2022
  • 资助金额:
    $ 26.02万
  • 项目类别:
mRNA stability and its impact on hematopoiesis and acute leukemia
mRNA稳定性及其对造血和急性白血病的影响
  • 批准号:
    10339742
  • 财政年份:
    2022
  • 资助金额:
    $ 26.02万
  • 项目类别:
Diversifying Acute Leukemia Clinical Trial Enrollment Through Multilevel Intervention
通过多层次干预使急性白血病临床试验招募多样化
  • 批准号:
    10505579
  • 财政年份:
    2022
  • 资助金额:
    $ 26.02万
  • 项目类别:
Clonal dynamics and chemoresistance mechanisms of minimal residual disease in acute leukemia
急性白血病微小残留病的克隆动力学和化疗耐药机制
  • 批准号:
    10351765
  • 财政年份:
    2022
  • 资助金额:
    $ 26.02万
  • 项目类别:
Anti-CD25 Radioimmunotherapy and Total Marrow Irradiation for Treatment of Relapsed and Refractory Acute Leukemia
抗CD25放射免疫治疗和全骨髓照射治疗复发难治性急性白血病
  • 批准号:
    10576955
  • 财政年份:
    2022
  • 资助金额:
    $ 26.02万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了